Protocol R2222-RSV-1332, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants

Project: Research project

Project Details

StatusActive
Effective start/end date10/14/15 → 8/31/50

Funding

  • Regeneron Pharmaceuticals, Inc.